早产儿中采用液体校正肌酐定义的急性肾损伤:PENUT随机临床试验的二次分析
本研究为PENUT随机临床试验的事后队列分析,纳入923例胎龄小于28周的极早产儿,比较未校正与液体校正肌酐定义的AKI及其与结局的关联。液体校正后AKI诊断比例由23.3%升至33.9%,新识别111例AKI(即被揭示的AKI)。多变量分析显示液体校正AKI与机械通气(校正OR 2.23;95%CI 1.56-3.18)和重度BPD(校正OR 2.05;95%CI 1.15-3.64)风险升高相关。作者认为,不校正液体平衡会低估早产儿AKI的患病率及影响。
要点
- 在923例胎龄<28周极早产儿中,未校正肌酐诊断AKI 215例(23.3%),液体校正后诊断313例(33.9%)。
- 液体校正后,13例原AKI被重新分类为无AKI,111例原无AKI被重新分类为液体校正AKI(即被揭示的AKI)。
- 被揭示的AKI患儿与未校正肌酐诊断AKI者临床特征相似;较无AKI者更可能需要通气(81例[75.0%] vs 254例[44.3%]),住院时间更长(中位[IQR] 102[84-124]天 vs 90[71-110]天)。
- 多变量分析中,液体校正AKI与通气风险升高相关(校正OR 2.23;95%CI 1.56-3.18),与重度BPD风险升高相关(校正OR 2.05;95%CI 1.15-3.64)。
- 作者认为,不校正血清肌酐的液体平衡会低估早产儿AKI的患病率及影响;未来研究应考虑对AKI进行液体平衡校正。
适用人群与场景
- 胎龄小于28周的极早产儿,来自美国19个学术中心和30个新生儿重症监护病房,2013年12月至2016年9月。
- 本分析为PENUT随机临床试验(促红细胞生成素3期试验)的事后队列分析。
诊断标准与关键阈值
- 液体校正AKI:在出生后前14天内诊断,液体校正血清肌酐定义为血清肌酐乘以液体平衡(按出生体重百分比变化计算)除以全身水量(估计为出生体重的80%)。
研究设计与关键结果
- 研究类型:PENUT随机临床试验的事后队列分析;样本量923例(男孩479例[51.9%];中位[IQR]出生体重801[668-940] g);人群为胎龄小于28周的极早产儿;暴露为出生后前14天内的液体校正AKI诊断。
- 主要终点为出生后第14天有创机械通气;次要终点包括死亡、住院时间和重度支气管肺发育不良(BPD)。
- 未校正肌酐诊断AKI 215例(23.3%);液体校正后诊断AKI 313例(33.9%)。
- 液体校正后,13例原AKI被重新分类为无液体校正AKI,111例原无AKI被重新分类为液体校正AKI(即被揭示的AKI)。
- 被揭示的AKI患儿与未校正肌酐诊断AKI者临床特征相似。
- 与无AKI者相比,被揭示的AKI患儿更可能需要通气(81例[75.0%] vs 254例[44.3%]),住院时间更长(中位[IQR] 102[84-124]天 vs 90[71-110]天)。
- 多变量分析中,液体校正AKI与通气风险升高相关(校正OR 2.23;95%CI 1.56-3.18),与重度BPD风险升高相关(校正OR 2.05;95%CI 1.15-3.64)。
证据类型、等级与局限
- 证据类型:随机临床试验的事后队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,不校正血清肌酐的液体平衡会低估早产儿AKI的患病率及影响。
- 作者认为,未来研究应考虑对AKI进行液体平衡校正。
指南或共识出处
- PENUT随机临床试验(ClinicalTrials.gov标识符NCT01378273)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute kidney injury (AKI) and disordered fluid balance are common in premature neonates; a positive fluid balance dilutes serum creatinine, and a negative fluid balance concentrates serum creatinine, both of which complicate AKI diagnosis. Correcting serum creatinine for fluid balance may improve diagnosis and increase diagnostic accuracy for AKI.
OBJECTIVE: To determine whether correcting serum creatinine for fluid balance would identify additional neonates with AKI and alter the association of AKI with short-term and long-term outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This study was a post hoc cohort analysis of the Preterm Erythropoietin Neuroprotection Trial (PENUT), a phase 3, randomized clinical trial of erythropoietin, conducted at 19 academic centers and 30 neonatal intensive care units in the US from December 2013 to September 2016. Participants included extremely premature neonates born at less than 28 weeks of gestation. Data analysis was conducted in December 2022.
EXPOSURE: Diagnosis of fluid-corrected AKI during the first 14 postnatal days, calculated using fluid-corrected serum creatinine (defined as serum creatinine multiplied by fluid balance [calculated as percentage change from birth weight] divided by total body water [estimated 80% of birth weight]).
MAIN OUTCOMES AND MEASURES: The primary outcome was invasive mechanical ventilation on postnatal day 14. Secondary outcomes included death, hospital length of stay, and severe bronchopulmonary dysplasia (BPD). Categorical variables were analyzed by proportional differences with the χ2 test or Fisher exact test. The t test and Wilcoxon rank sums test were used to compare continuous and ordinal variables, respectively. Odds ratios (ORs) and 95% CIs for the association of exposure with outcomes of interest were estimated using unconditional logistic regression models.
RESULTS: A total of 923 premature neonates (479 boys [51.9%]; median [IQR] birth weight, 801 [668-940] g) were included, of whom 215 (23.3%) received a diagnosis of AKI using uncorrected serum creatinine. After fluid balance correction, 13 neonates with AKI were reclassified as not having fluid-corrected AKI, and 111 neonates previously without AKI were reclassified as having fluid-corrected AKI (ie, unveiled AKI). Therefore, fluid-corrected AKI was diagnosed in 313 neonates (33.9%). Neonates with unveiled AKI were similar in clinical characteristics to those with AKI whose diagnoses were made with uncorrected serum creatinine. Compared with those without AKI, neonates with unveiled AKI were more likely to require ventilation (81 neonates [75.0%] vs 254 neonates [44.3%] and have longer hospital stays (median [IQR], 102 [84-124] days vs 90 [71-110] days). In multivariable analysis, a diagnosis of fluid-corrected AKI was associated with increased odds of adverse clinical outcomes, including ventilation (adjusted OR, 2.23; 95% CI, 1.56-3.18) and severe BPD (adjusted OR, 2.05; 95% CI, 1.15-3.64).
CONCLUSIONS AND RELEVANCE: In this post hoc cohort study of premature neonates, fluid correction increased the number of premature neonates with a diagnosis of AKI and was associated with increased odds of adverse clinical outcomes, including ventilation and BPD. Failing to correct serum creatinine for fluid balance underestimates the prevalence and impact of AKI in premature neonates. Future studies should consider correcting AKI for fluid balance.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01378273.
参考来源
- Starr MC, Griffin RL, Harer MW, et al. Acute Kidney Injury Defined by Fluid-Corrected Creatinine in Premature Neonates: A Secondary Analysis of the PENUT Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37561461. doi:10.1001/jamanetworkopen.2023.28182
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。